Akorn, Inc. and Hyaluron Contract Manufacturing (HCM) have signed a development and supply agreement for two ANDA injectable suspension products. One of the products is an injectable sustained release pharmaceutical, which will be available in both prefilled syringe and vial configurations. The second ANDA product is an anti-inflammatory and will be available in multiple packaging configurations. Hyaluron will manufacture both drug products for Akorn, which will be responsible for marketing...